[Endoluminal brachytherapy in the treatment of cancer of the oesophagus]
Record ID 32010001488
This study sought to: assess the effectiveness of high-dose-rate endoluminal brachytherapy in the treatment of oesophageal cancer, in terms of recurrence, survival, control of symptoms and patients' quality of life; and ascertain the safety of this procedure in terms of the toxicity of radiotherapy.
Brachytherapy of a palliative nature could be considered in oesophageal cancers with unresectable lesions or distant metastases. In such cases, high-dose-rate brachytherapy has proved to be a swift and effective method of relieving dysphagy and a suitable alternative to stents. Using a fractionation schedule, a dose range of 12 to 15 Gy would be advisable.Brachytherapy could also be used for localised, early-stage tumours, where these were not operable or where patients rejected surgery, were of an advanced age or had a poor clinical condition. The main adverse effects of the technique are development of oesophageal stenosis and fistulae, and haemorrhages. Minor complications include mild retrosternal pain and postradiation oesophagitis.
English language abstract:
An English language summary is available
Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Galician Agency for Health Technology Assessment (AVALIA-T)